FIELD: medicine.
SUBSTANCE: invention relates to a method for producing a betulin-based adjuvant for the vaccine against SARS-CoV-2 coronavirus, which provides for sterilizing filtration of a betulin solution in tetrahydrofuran through a nylon membrane with a pore diameter of 0.22 mcm, reducing the content of tetrahydrofuran by adding a 25-fold volume of sterile 0.01 M tris-buffer (pH-9.0±0.1) using a peristaltic pump with constant mixing for 15 minutes with a propeller-type magnetic mixer, followed by ultrasound homogenization at 35-40 kHz for 10 minutes until a homogeneous suspension is obtained with the formation of spherical amorphous homogeneous particles on which proteins of SARS-CoV-2 virus are sorbed.
EFFECT: proposed is method for obtaining a betulin-based adjuvant for the vaccine against SARS-CoV-2 coronavirus with high sterility and immunogenicity, which improves the quality of the vaccine against coronavirus.
4 cl, 6 dwg, 9 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PENTAVALENT SUBUNIT VACCINE AGAINST RESPIRATORY INFECTIONS AND METHOD OF ITS PREPARATION | 2022 |
|
RU2804948C2 |
| HYBRID GENE CONSISTING OF THE RBD RECEPTOR OF THE SURFACE PROTEIN S OF SARS-CoV-2 CORONAVIRUS, S14P5 AND S21P2 EPITOPES, Fc FRAGMENT, FOR OBTAINING A RECOMBINANT ANTIGEN AND ITS USE AS PART OF A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION | 2022 |
|
RU2795160C1 |
| METHOD OF PRODUCTION OF ADJUVANT FOR VIRAL VACCINES | 2014 |
|
RU2545714C1 |
| METHOD OF PRODUCING ADJUVANT FOR VACCINE | 2014 |
|
RU2545717C1 |
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| RECOMBINANT VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 | 2021 |
|
RU2769224C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| POLYPEPTIDE MODULE FOR BINDING CONSERVATIVE EPITOPE OF RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 CORONAVIRUS | 2022 |
|
RU2809183C1 |
